2021-09-24T14:54:27-05:00 2020-12-31 BKD LLP 1155 Avenue of the Americas 1200 NEW YORK NY 10036 990 2020-01-01 362883000 American Liver Foundation % DAVID TICKER AMER 2126681000 PO BOX 299 West Orange NJ 07052 DAVID TICKER CFO 2126681000 2021-11-15 true David Ticker 999009999 Aaron Shapiro P01333816 2128674000 3 2020 2022-09-23 18:48:47Z X DAVID TICKER PO BOX 299 WEST ORANGE NJ 07052 6145538 false X WWW.LIVERFOUNDATION.ORG X 1976 NY OUR MISSION IS TO FACILITATE, ADVOCATE, AND PROMOTE EDUCATION, SUPPORT SERVICES, AND RESEARCH FOR THE PREVENTION, TREATMENT, AND CURE OF LIVER DISEASE. 22 21 61 1000 0 8927298 5317288 0 0 103785 100795 -179794 85146 8851289 5503229 275000 150000 0 0 5391464 3749868 0 0 614514 3071102 1984475 8737566 5884343 113723 -381114 5267197 5773717 1566244 2371898 3700953 3401819 X OUR MISSION IS TO FACILITATE, ADVOCATE, AND PROMOTE EDUCATION, SUPPORT SERVICES, AND RESEARCH FOR THE PREVENTION, TREATMENT, AND CURE OF LIVER DISEASE. false true 1144199 PUBLIC AND PATIENT EDUCATION: Since the start of the COVID-19 pandemic in early 2020, patient education has focused primarily on the relationship of COVID-19 and the liver. People with underlying health conditions such as liver disease have both an elevated risk for COVID-19 infection and, should they contract the virus, more severe complications. The Foundation tapped into its medical advisory resources to provide a general understanding of the virus and its impact to patients with liver disease. Patient education around liver disease and COVID-19 included webinars, blog posts, and educational videos. The Foundation's COVID-related educational video series included the following topics: . Coronavirus and the Liver . Healthy Eating at Home . Update on COVID-19 . Questions for an Infectious Disease Specialist about COVID-19 . COVID-19 and Liver Transplantation . Being a Caregiver During COVID-19 . The Spread of COVID-19 in the Latino Community and Latino Liver Patients . Children with Liver Disease Living through COVID-19 . COVID-19 and Fatty Liver Disease . COVID-19 and Hepatitis Awareness Month Recognizing that emotional well-being is part of the patient experience and the additional stress from the pandemic, the Foundation also developed wellness and coping tools such as "How to Explain COVID to KidsMind-Body webinars. The Liver Lowdown e-newsletter is disseminated to provide information about the prevention, treatment and cure of liver about the Foundation's educational and signature programs, an in-depth focus on specific types of liver disease, and profiles of liver patientscaregivers' personal experiences. In 2020, over 130,000 people received each of our issues. The American Liver Foundation's digital content allows us to reach millions of people with our information and resource. The ALF website helps us better deliver quality programs and events to our constituents including multimedia webinars, videos and broadcasts. We've seen a steady rise in use with approximately 5 million-page views in 2020 from 3.5 million just two years ago in 2018. At the end of 2020, we had over 158,000 Facebook fans and over 7,000 Twitter followers. Our support community on the Inspire platform had over 26,000 members. ALF released two podcasts in 2020. One during Donate Life Month and another episode for World Hepatitis Day, in collaboration with the CDC Division of Viral Hepatitis. ALF expanded its educational resource library by creating updated and new resources on clinical trials, liver cancer and Acute Hepatic Porphyria. All brochures are available for download from our website at https://liverfoundation.org/for-patients/resources/brochures/. ALF held a virtual HCC patient conference in 2020. This conference provided educational sessions and resources for HCC patients and caregivers that are not eligible for a transplant. 100 people attended this event. The ALF convened a NASH Roundtable to understand the needs of people diagnosed with NASH & identify solutions for empowering them to take an active role in managing their liver health. Participants included NASH patients, caregivers, representatives from patient advocacy organizations, hematologists, and primary care providers. Using the findings from the Roundtable, we have created a NASH Patient Bill of Rights and Physician Discussion Guide. 1181018 PATIENT SUPPORT: Information specialists are available to answer questions about liver disease and liver wellness, including risk factors, prevention, symptoms, early detection, diagnosis and treatment options. ALF can direct callers to local services in their area, help them learn about clinical trials and help them find a physician. Interpretation services are available for non-English speakers. We also host a vibrant online community across numerous social media platforms and one website. In CY 2020, our Help Line answered nearly 7,000 requests for information via phone, e-chat, email and the postal service. While the majority of requests came from within the United States, 20% were international contacts. The five states with the largest populations - California, Texas, Florida, New York, and Pennsylvania -Accounted for 22% of all inquiries. The COVID-19 pandemic which affected all Americans posed additional health risks to people with underlying health conditions such as liver disease. The Helpline received over 70 types of COVID-related inquiries in 2020. Questions ranged from where to find more information about the virus to vaccination questions such as vaccine options, safety, and prioritization for people with liver disease. Anticipating the increase in COVID-related inquiries, staff participated in multiple webinars to learn as much as possible about COVID-19 so the information they shared with HelpLine visitors was accurate. Additionally, HelpLine staff regularly visit the Centers for Disease Control and Prevention (CDC) website, where COVID-19 information is updated frequently to ensure that the information the Foundation distributes is accurate when provided at the time of requests. The American Liver Foundation's Primary Biliary Cholangitis Facebook Support Group currently has over 2,800 members and is our first and largest Facebook Support Community that was started in 2017. The NASH Facebook Support Group, a support community for those affected by Nonalcoholic Steatohepatitis (NASH) has grown significantly since its inception in 2018. The group currently has over 1,900 members from 522 members in 2018. This group is open to anyone connected to NASH around the country and serves as a space to feel less alone and seek answers to questions they may have about their journey. In late 2020, we created a new Facebook support group for Liver Cancer patients and their loved ones. This group has nearly 100 members and is continuing to grow daily. ALF's National Patient Advisory Committee, made up of patient advocates from across the country with hepatitis C, NAFLD, primary biliary cholangitis, Hepatic Encephalopathy and alcohol-related liver disease, Hepatorenal Syndrome, and in 2020 we expanded the group further to add patient advocates with NASH and Liver Cancer. 1103198 COMMUNITY SERVICES: ALF offers several Community Education Programs on liver health and liver disease that are interactive and age appropriate. These popular programs include: Love Your Liver, Liver Wellness - What Everybody Needs to Know, Teens to Twenties - Liver Wellness Guide, Non-Alcoholic Fatty Liver Disease, and Alcohol-Related Liver Disease. In addition, ALF participates in community health fairs and coalition meetings to raise awareness of liver disease. Despite the pandemic, ALF still delivered community education programs virtually when possible. In 2020, ALF reached 4,097 people through our community education programs. ALF conducts advocacy work on behalf of the patient community throughout the year, actively lobbying federal, state, and local governments on pertinent legislation affecting the liver community. The Foundation has been a moving force behind the acceptance of an agreement on a comprehensive "Research Agenda" for liver disease. Additionally, the Foundation has been active in obtaining cosponsors for the Liver Research Enhancement Act (HR1743) to create a center within the National Institutes for Health that will focus solely on research into liver-related diseases. With many patients with liver disease requiring liver transplants, the Foundation has resolutely lobbied Congress and state legislatures for legislation to support increases in organ donations. The American Liver Foundation has over 900 constituents signed up on our advocacy platform and we regularly share action alerts and important issues for liver patients. Due to COVID restrictions, the Foundation pivoted from an in-person "Annual Day on the Hill" meetings to "Advocacy Week" in 2020 where staff, patients, and volunteers virtually met with legislators to discuss pertinent issues and legislative priorities. Whether in-person or virtual, advocates receive training which encompasses a legislative update, review of the issues, the Foundation's positions on these issues, and best practices to engage legislators. In 2019, over 60 people attended Hill Day in Washington D.C. and in 2020 we had over 100 people attend our virtual Advocacy Week. The ALF has participated in the AASLD Annual Hill Day and the Digestive Disease National Coalition Public Policy Forum in 2020. 1117919 150000 RESEARCH AND PROFESSIONAL EDUCATION 1117919 150000 4546334 true true false false false false false false true true true false false false true false true false false false false false false false true false false true false true false false false false false false false false false false false false false false false false false true 78 0 61 true false false false false false true true false false false true false false false X 22 21 false false false false false false false true true false true true true true true true true true true true false AL AK AZ AR AP CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X DAVID TICKER 2126681000 PO BOX 299 WEST ORANGE NJ 07052 DAVID TICKER CFO 35.0 0.0 X 150283 0 18630 LYNN SEIM COO 35.0 0.0 X 152437 0 5788 KELLY SMITH NATIONAL DIRECTOR - EVENTS 35.0 0.0 X 102780 0 43010 ERIKA GOODMAN NAT'L DIRECTOR OF DEVELOPMENT 35.0 0.0 X 122828 0 19320 KATHLEEN FLYNN NAT'L SR. DIR - ENGAGEMENT 35.0 0.0 X 121218 0 16605 VERONICA PEREZ NATIONAL DIRECTOR - INDIVIDUAL 35.0 0.0 X 113754 0 13302 FARRAH DOUGLAS NATIONAL DIRECTOR - ENGAGEMENT 35.0 0.0 X 109483 0 14629 THOMAS F NEALON III CEO till 4/20/board member 35.0 0.0 X X 71684 0 35728 DANIEL E WEIL BOARD CHAIR 0.3 0.0 X X 0 0 0 GENE CAUTILLO SECRETARY 0.3 0.0 X X 0 0 0 SUSAN SHERMAN STONE CPA MST TREASURER 0.3 0.0 X X 0 0 0 Nicholas J Deroma board member 0.3 0.0 X 0 0 0 EDDIE CHEUNG MD FACG BOARD MEMBER 0.3 0.0 X 0 0 0 ALLAN J DOERR BOARD MEMBER 0.3 0.0 X 0 0 0 T CLARK GAMBLIN MD MS MBA BOARD MEMBER 0.3 0.0 X 0 0 0 MARY ANN HUANG MD MS BOARD MEMBER 0.3 0.0 X 0 0 0 MICHAEL KERR BOARD MEMBER 0.3 0.0 X 0 0 0 ELIZABETH LEESMANN BOARD MEMBER 0.3 0.0 X 0 0 0 ROHIT LOOMBA MD BOARD MEMBER 0.3 0.0 X 0 0 0 SAMMY SAAB MD MPH BOARD MEMBER 0.3 0.0 X 0 0 0 NICOLE SMITH PHD BOARD MEMBER 0.3 0.0 X 0 0 0 Mike Braunstein board member 0.3 0.0 X 0 0 0 EMMANUEL THOMAS MD PHD BOARD MEMBER 0.3 0.0 X 0 0 0 TRACI TIGUE BOARD MEMBER 0.3 0.0 X 0 0 0 HILLEL TOBIAS MD PHD BOARD MEMBER 0.3 0.0 X 0 0 0 ROCKY YAPP MD MPH AGAF BOARD MEMBER 0.3 0.0 X 0 0 0 STEVE BAUM BOARD MEMBER 0.3 0.0 X 0 0 0 Robert Brickman board member 0.3 0.0 X 0 0 0 Robert Merowitz board member 0.3 0.0 X 0 0 0 944467 0 167012 8 false true false JPA HEALTH COMMUNICATIONS 1101 CONNECTICUT AVE NW WASHINGTON DC 20036 PUBLIC RELATIONS 103951 AMPLOTECH LLC PO BOX 16422 SAN JUAN PR 00908 MARKETING 117038 2 12799 1700569 3603920 5317288 0 45040 45040 0 0 0 0 0 482213 426458 55755 55755 55755 116700 1700569 215851 -99151 -99151 0 0 0 0 0 0 OTHER 900099 184297 184297 184297 5503229 185941 150000 150000 0 0 0 0 434550 337262 54100 43188 0 2681141 2080882 333794 266465 15654 12149 1949 1556 371549 288367 46256 36926 246974 191681 30748 24545 0 136550 113792 9306 13452 0 0 0 14260 14260 111777 93148 7618 11011 257941 216451 15999 25491 211058 88594 68816 53648 258185 201564 32292 24329 0 599352 471797 70869 56686 75144 63561 5420 6163 0 0 7690 7690 0 26443 20523 3292 2628 49551 38457 6169 4925 HOTEL AND CATERING 153627 129396 9132 15099 MISCELLANEOUS 82897 48710 5785 28402 5884343 4546334 723495 614514 1791670 2422890 11538 21891 196618 180798 0 0 0 0 0 0 0 0 0 0 191894 88292 1314633 1293955 47121 20678 3028356 3039168 0 0 0 0 0 0 0 0 5267197 5773717 572902 867078 137500 75000 0 0 0 0 774204 669521 0 0 0 0 0 737979 81638 22320 1566244 2371898 X 614131 632568 3086822 2769251 3700953 3401819 5267197 5773717 -381114 81980 X false true X true false X 7306322 6597397 9257672 8927298 5317288 37405977 0 0 7306322 6597397 9257672 8927298 5317288 37405977 7228574 30177403 52306 55931 58839 73774 45040 285890 0 15001 25994 25653 35890 184297 286835 37978702 0.79459 0.80333 X part Ii AMERICAN LIVER FOUNDATION CHANGED THEIR YEAR-END IN 2015 FROM SEPTEMBER 30 TO DECEMBER 31. THE DATA IN 2015 REPRESENTS THE 3 MONTHS ENDED DECEMBER 31, 2015. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true 1222206 95449 329540 988115 1112588 222118 112500 1222206 1215883 -75352 27943 1112588 1103423 174960 62500 1215883 1095696 57727 50000 1103423 0.75100 0.24900 false false 97448 97448 0 465745 461226 4519 751440 735281 16159 20678 0 DEFERRED RENT 22320 22320 5680090 81980 134141 216121 5463969 14260 25000 39260 5503229 5979224 134141 134141 5845083 14260 25000 39260 5884343 PART IV, LINE 2B FUNDS HELD ON BEHALF OF OTHERS - ALF ACTS AS AN ADMINISTRATOR FOR FUNDS COLLECTED ON BEHALF OF LIVER TRANSPLANT PATIENTS. ALF DISBURSES FUNDS TO COVER THE COST OF PROPERLY DOCUMENTED POST-SURGERY EXPENSES. PART V, LINE 4 THE INTENDED USE OF ENDOWMENT FUNDS HAS BEEN SPECIFIED BY THE DONOR. ALL FUNDS ON HAND ARE USED TO GENERATE INTEREST/DIVIDEND INCOME AND CAPITAL GAINS TO SUPPORT VARIOUS RESEARCH INITIATIVES. SCHEDULE D, PART X, LINE 2 ASC 740 FOOTNOTE MANAGEMENT HAS EVALUATED THEIR INCOME TAX POSITIONS UNDER THE GUIDANCE INCLUDED IN ASC 740. BASED ON THEIR REVIEW, MANAGEMENT HAS NOT IDENTIFIED ANY MATERIAL UNCERTAIN TAX POSITIONS TO BE RECORDED OR DISCLOSED IN THE FINANCIAL STATEMENTS. Part XI, Line 4b Refunded grant: 25,000 Part XII, line 4b Refunded grant: 25,000 CUISINE FOR A C 823303 706603 116700 67024 108716 LIVER LIFE WALK 620446 620446 15057 6 373520 373520 25054 1817269 1700569 116700 67024 148827 215851 -99151 true COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK NY 10027 135598093 501(C)(3) 75000 LIVER DISEASE RESEARCH THOMAS JEFFERSON UNIVERSITY 1020 WALNUT STREET PHILADELPHIA PA 19107 231352651 501(C)(3) 75000 LIVER DISEASE RESEARCH 2 SCHEDULE I, PART I, LINE 2 ANNUAL REPORTS DETAILING RESEARCH FINDINGS ARE SUBMITTED IN ORDER TO MAINTAIN FUNDING. X X false false false false false false false false false LYNN SEIM COO 152437 0 0 0 0 0 1540 0 4248 0 158225 0 DAVID TICKER CFO 150283 0 0 0 0 0 1540 0 17090 0 168913 0 FORM 990, PART III, LINE 3 Due to COVID-19 ALL PROGRAMS WERE DELIVERED VIRTUALLY DURING 2020. FORM 990, PART VI, SECTION B, LINE 11B A DRAFT OF THE FORM 990 IS SENT TO THE FINANCE COMMITTEE FOR REVIEW AND COMMENTS IN THE MONTHLY MEETING PRIOR TO FILING. IN ADDITION, A DRAFT OF THE FORM 990 IS ALSO SENT TO EACH BOARD MEMBER FOR DISCUSSION. AFTER QUESTIONS AND COMMENTS ARE ADDRESSED AND THE FORM 990 IS APPROVED, IT IS READY FOR FILING. FORM 990, PART VI, SECTION B, LINE 12C ANNUALLY, OUR CONFLICT OF INTEREST FORM IS COMPLETED BY OFFICERS AND DIRECTORS. THE FORM MUST INDICATE ANY POSSIBLE CONFLICTS OF INTEREST AND BE SIGNED BY ALL OFFICERS AND DIRECTORS. WHEN ANY SUCH CONFLICT OF INTEREST IS RELEVANT TO A MATTER REQUIRING ACTION BY THE BOARD, THE INTERESTED PERSON SHALL CALL IT TO THE ATTENTION OF THE BOARD AND SUCH PERSON SHALL NOT VOTE ON THE MATTER. MOREOVER, THE PERSON HAVING A CONFLICT SHALL RETIRE FROM THE ROOM IN WHICH THE BOARD IS MEETING AND SHALL NOT PARTICIPATE IN THE FINAL DELIBERATION OR DECISION REGARDING THE MATTER UNDER CONSIDERATION. HOWEVER, THAT PERSON SHALL PROVIDE THE BOARD WITH ANY AND ALL RELEVANT INFORMATION. THE MINUTES OF THE MEETING OF THE BOARD, SHALL REFLECT THAT THE CONFLICT OF INTEREST WAS DISCLOSED AND THAT THE INTERESTED PERSON WAS NOT PRESENT DURING THE FINAL DISCUSSION OR VOTE AND DID NOT VOTE. WHEN THERE IS A DOUBT AS TO WHETHER A CONFLICT OF INTEREST EXISTS, THE MATTER SHALL BE RESOLVED BY A VOTE OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 15A CEO COMPENSATION IS DETERMINED BY THE NATIONAL BOARD OF DIRECTOR'S EXECUTIVE COMMITTEE AND APPROVED BY THE BOARD MEMBERS. IN DETERMINING SALARY LEVELS, THE EXECUTIVE COMMITTEE REVIEWS AN ANNUAL SALARY SURVEY OF NATIONAL VOLUNTARY HEALTH ORGANIZATIONS PREPARED FOR THE NATIONAL HEALTH COUNCIL AND REVIEWS PRIOR YEAR PERFORMANCE. CURRENT MARKET CONDITIONS AND THE FINANCIAL CONDITION OF THE AMERICAN LIVER FOUNDATION ARE ALSO CONSIDERED IN SETTING COMPENSATION. THIS REVIEW WAS LAST CONDUCTED IN 2020. FORM 990, PART VI, SECTION B, LINE 15B THE SALARY OF OFFICERS AND KEY EMPLOYEES ARE DETERMINED BY THE CEO & CFO BASED ON PERFORMANCE, MARKET CONDITIONS AND THE FINANCIAL CONDITION OF THE AMERICAN LIVER FOUNDATION. FORM 990, PART VI, SECTION C, LINE 19 THE FORM 990 IS AVAILABLE VIA WWW.LIVERFOUNDATION.ORG AND FORM 1023 IS AVAILABLE UPON REQUEST.